4M ANALYTICS is a subsurface-infrastructure geo-data company. We developed a mapping engine for utility and infrastructure construction project life cycle, for the pre planning and planning phase, an early comprehensive, mapping simulation tool before the project handed off to the design builder and constructor. Our technology is powered by deep expertise in applying AI and analytics to satellite and aerial imagery analysis for the civil engineering domain. We provide complete, accurate and up to date subsurface infrastructure maps. Our maps are created remotely using AI, without the need for prior as-built data, anywhere in the world and at unprecedented scale and super low cost.
AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for viral-associated diseases. Its lead product, Viralym-M, targets several viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline also includes candidates for treating respiratory syncytial virus, influenza, SARS-CoV-2, hepatitis B, and human herpesvirus-8. AlloVir's proprietary VST therapy platform aims to provide accessible treatment options for patients facing severe viral infections, addressing the pressing need for effective therapies in this area. Founded in 2013, AlloVir was previously known as ViraCyte, Inc. and rebranded in May 2019.
AcroCharge provides the charge-back mitigation solutions to eCommerce merchants.
Five Sigma LTD. is an insurtech company based in Tel Aviv-Yafo, Israel, that specializes in developing software to automate the claims management process for insurance carriers. Founded in 2017, the company offers a cloud-based, end-to-end SaaS platform designed to enhance customer experience, reduce operational costs, and lower loss ratios. Five Sigma's data-driven claims management system enables insurers to gain valuable insights into pricing, underwriting, and risk management, thereby transforming the traditional claims handling approach.
Five Sigma LTD. is an insurtech company based in Tel Aviv-Yafo, Israel, that specializes in developing software to automate the claims management process for insurance carriers. Founded in 2017, the company offers a cloud-based, end-to-end SaaS platform designed to enhance customer experience, reduce operational costs, and lower loss ratios. Five Sigma's data-driven claims management system enables insurers to gain valuable insights into pricing, underwriting, and risk management, thereby transforming the traditional claims handling approach.
4M ANALYTICS is a subsurface-infrastructure geo-data company. We developed a mapping engine for utility and infrastructure construction project life cycle, for the pre planning and planning phase, an early comprehensive, mapping simulation tool before the project handed off to the design builder and constructor. Our technology is powered by deep expertise in applying AI and analytics to satellite and aerial imagery analysis for the civil engineering domain. We provide complete, accurate and up to date subsurface infrastructure maps. Our maps are created remotely using AI, without the need for prior as-built data, anywhere in the world and at unprecedented scale and super low cost.
Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.
Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.
ElevateBio, LLC, based in Cambridge, Massachusetts, is a holding company focused on the development of cell and gene-based therapies. Established in 2017, ElevateBio operates a portfolio of subsidiary companies that aim to create innovative treatments for cancer and viral infections. The company partners with leading scientists and inventors to foster its portfolio and has established a centralized facility designed to streamline the translation of research and development into commercially viable therapies. This integrated approach enables the efficient development, manufacturing, and commercialization of life-transforming medicines, ultimately helping to provide patients with effective treatments for severe diseases.
AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for viral-associated diseases. Its lead product, Viralym-M, targets several viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline also includes candidates for treating respiratory syncytial virus, influenza, SARS-CoV-2, hepatitis B, and human herpesvirus-8. AlloVir's proprietary VST therapy platform aims to provide accessible treatment options for patients facing severe viral infections, addressing the pressing need for effective therapies in this area. Founded in 2013, AlloVir was previously known as ViraCyte, Inc. and rebranded in May 2019.
TriNetX, Inc. is a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a platform that enables researchers to analyze patient populations and derive real-world evidence, thereby enhancing trial design and improving site selection. Key offerings include TriNetX Live, a cloud-based solution for real-time analytics; TriNetX Research, which delivers longitudinal clinical data; and TriNetX Download, a platform for accessing real-world clinical data. Additionally, TriNetX features Attract Trials for data alignment in collaboration, Natural Language Processing for extracting clinical insights from physician documentation, and specialized tools for oncology research. Established in 2013 and headquartered in Cambridge, Massachusetts, TriNetX also has offices in Sydney, London, and Sao Paulo, and maintains compliance with HIPAA and GDPR regulations.
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company focused on developing innovative T cell receptor therapies for cancer treatment. The company's lead product candidates include TC-210, a TRuC-T cell therapy targeting mesothelin-positive solid tumors, which is currently undergoing a phase I/II clinical trial for various cancers, including non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Another key candidate is TC-110, designed to target CD19-positive B-cell hematological malignancies. TCR2's pipeline also addresses adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company, founded in 2015 and headquartered in Cambridge, Massachusetts, leverages advanced technologies and a deep understanding of T cell receptor biology to create therapies that differ from traditional CAR-T treatments and enhance T cell engagement in recognizing and destroying cancer cells.
Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company focused on developing innovative T cell receptor therapies for cancer treatment. The company's lead product candidates include TC-210, a TRuC-T cell therapy targeting mesothelin-positive solid tumors, which is currently undergoing a phase I/II clinical trial for various cancers, including non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Another key candidate is TC-110, designed to target CD19-positive B-cell hematological malignancies. TCR2's pipeline also addresses adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company, founded in 2015 and headquartered in Cambridge, Massachusetts, leverages advanced technologies and a deep understanding of T cell receptor biology to create therapies that differ from traditional CAR-T treatments and enhance T cell engagement in recognizing and destroying cancer cells.
iPrice Group Sdn Bhd operates an e-commerce platform. The company offers electronics, clothing, shoes, bags, watches, jeweler, kids and toys, sports and outdoors, and home and living products. The company also provides products in various categories, such as kitchen and dining, cooling, women’s ethnic wear, skin care, men’s sneakers, strollers and carriers, makeup, backpacks, women’s dresses, accessories, food supplements, hair care, smartphones, LED, cases and covers, men’s shoes, gadgets, women’s heels, sport, fashion watches, travel, headphones, bedroom, casual, beauty and health, medical equipment, and cycling products. It serves clients in Malaysia, Singapore, Indonesia, the Philippines, Hong Kong, Thailand, and Vietnam. The company was founded in 2014 and is headquartered in Kuala Lumpur, Malaysia.
Clinical Ink, Inc. specializes in providing eSource and patient engagement solutions tailored for the clinical research sector, assisting sites, sponsors, and contract research organizations (CROs) in streamlining their processes. The company's primary offering, SureSource, is an electronic source platform designed to capture essential clinical trial data and documents directly at the research site. Additionally, Clinical Ink provides Lunexis ePRO+, which facilitates patient participation by allowing flexible engagement options, and CentrosHealth, a platform that keeps patients informed and compliant throughout their clinical trial experience. Founded in 2006, Clinical Ink operates its headquarters in Horsham, Pennsylvania, and has additional offices in Winston-Salem, Cary, Philadelphia, and Cambridge. The company aims to enhance clinical trial workflows and improve data quality through its innovative electronic source solutions.
Chiasma (Israel) Ltd. is a biopharmaceutical company specializing in the development of oral drugs utilizing its proprietary Transient Permeability Enhancer technology. Founded in 2001 and based in Ness Ziona, Israel, the company focuses on transforming injectable drugs into oral formulations, thereby enhancing their absorption and potentially enabling new therapeutic indications. Its primary product is oral octreotide acetate, designed for the treatment of acromegaly, a rare condition. Chiasma's pipeline includes novel drugs aimed at addressing unmet medical needs in well-defined markets, with a particular emphasis on orphan indications. The company operates as a subsidiary of Chiasma, Inc., and is dedicated to improving the treatment options for patients with rare and debilitating diseases.
ProterixBio, Inc. specializes in developing disease management platforms aimed at improving patient outcomes in chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company utilizes its proprietary ViBE platform and Acoustic Membrane MicroParticle (AMMP) assays to facilitate the precise analysis of proteins in various biological samples, including blood and sputum. The AMMP technology employs a non-optical, homogeneous assay approach, which enhances the sensitivity and specificity of traditional reagents through the integration of biological capture strategies and advanced acoustic sensors. By providing real-time biological assessments of a patient's disease state, ProterixBio's products support healthcare providers in managing chronic conditions more effectively, reducing the need for hospitalizations, and ultimately lowering healthcare costs. Founded in 2002 and based in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in May 2016.
ProterixBio, Inc. specializes in developing disease management platforms aimed at improving patient outcomes in chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company utilizes its proprietary ViBE platform and Acoustic Membrane MicroParticle (AMMP) assays to facilitate the precise analysis of proteins in various biological samples, including blood and sputum. The AMMP technology employs a non-optical, homogeneous assay approach, which enhances the sensitivity and specificity of traditional reagents through the integration of biological capture strategies and advanced acoustic sensors. By providing real-time biological assessments of a patient's disease state, ProterixBio's products support healthcare providers in managing chronic conditions more effectively, reducing the need for hospitalizations, and ultimately lowering healthcare costs. Founded in 2002 and based in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in May 2016.
Chiasma (Israel) Ltd. is a biopharmaceutical company specializing in the development of oral drugs utilizing its proprietary Transient Permeability Enhancer technology. Founded in 2001 and based in Ness Ziona, Israel, the company focuses on transforming injectable drugs into oral formulations, thereby enhancing their absorption and potentially enabling new therapeutic indications. Its primary product is oral octreotide acetate, designed for the treatment of acromegaly, a rare condition. Chiasma's pipeline includes novel drugs aimed at addressing unmet medical needs in well-defined markets, with a particular emphasis on orphan indications. The company operates as a subsidiary of Chiasma, Inc., and is dedicated to improving the treatment options for patients with rare and debilitating diseases.
Chiasma (Israel) Ltd. is a biopharmaceutical company specializing in the development of oral drugs utilizing its proprietary Transient Permeability Enhancer technology. Founded in 2001 and based in Ness Ziona, Israel, the company focuses on transforming injectable drugs into oral formulations, thereby enhancing their absorption and potentially enabling new therapeutic indications. Its primary product is oral octreotide acetate, designed for the treatment of acromegaly, a rare condition. Chiasma's pipeline includes novel drugs aimed at addressing unmet medical needs in well-defined markets, with a particular emphasis on orphan indications. The company operates as a subsidiary of Chiasma, Inc., and is dedicated to improving the treatment options for patients with rare and debilitating diseases.
ProterixBio, Inc. specializes in developing disease management platforms aimed at improving patient outcomes in chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company utilizes its proprietary ViBE platform and Acoustic Membrane MicroParticle (AMMP) assays to facilitate the precise analysis of proteins in various biological samples, including blood and sputum. The AMMP technology employs a non-optical, homogeneous assay approach, which enhances the sensitivity and specificity of traditional reagents through the integration of biological capture strategies and advanced acoustic sensors. By providing real-time biological assessments of a patient's disease state, ProterixBio's products support healthcare providers in managing chronic conditions more effectively, reducing the need for hospitalizations, and ultimately lowering healthcare costs. Founded in 2002 and based in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in May 2016.